Safety and Efficacy Study of NV-101 in Dental Patients

Novalar Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Soft Tissue Anesthesia (Numbness)

Treatments

Drug: NV-101 (phentolamine mesylate solution)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00154167

NOVA 03-001

Details and patient eligibility

About

The purpose of this study was:

to determine if NV-101 accelerates recovery from numbness compared to placebo
to evaluate safety of NV-101

Full description

This was a randomized, double-blind, placebo-controlled, multi-center study. One hundred twenty-two patients aged 10-58 requiring treatment with one of four routine dental procedures were enrolled. The investigators were licensed dentists in private practice. Each patient received one or more conventional injections of either articaine with epinephrine, lidocaine with epinephrine, prilocaine with epinephrine, or mepivacaine with levonordefrin. Local anesthetics were injected into no more than 2 sites. Injections of local anesthetic placed within 4mm of each other constituted the same site. The injection(s) of study drug were made at or near the completion of the dental procedure and were required to be not earlier than 20 minutes after, and not later than 70 minutes after, the most recent injection of local anesthetic. Patients received an injection of study drug (1.8 mL) in each site at which local anesthetic had been injected (i.e. no more than 2 sites).

Patients self-evaluated the return of normal sensation in the lip, tongue, nose, and chin by palpations at 5-minute intervals beginning 1 minute before the study drug injection and continuing for a minimum of 3 hours and until they achieved the return of normal sensation in lip, tongue, nose, and chin.

Safety was assessed by the use of a Holter monitor, vital signs, pain ratings, and physical examinations including oral cavity examinations.

Sex

All

Ages

10 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Between 10-65 years of age
Body weight between 35 to 110 kg
Healthy as determined by the Investigator based on medical history, physical examination, and 12 Lead ECG
Clinical laboratory tests within the reference ranges or within clinically acceptable limits according to the Investigator
Normal lip, nose, chin, and tongue sensations
Women of childbearing potential must have agreed to use barrier contraception for the duration of the study (Women of childbearing potential included all women except for those who are premenstrual, whose menstrual periods have not occured for greater than or equal to one year after menopause, who are surgically sterilized, or who have had a hysterectomy)
Can understand and sign the informed consent document, can communicate with the investigator, and can understand and comply with the requirements of the protocol

Exclusion criteria

Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue disease or disorder
Clinically relevant surgical history
History of alcoholism and/or drug abuse within the past 5 years
Significant infection or known inflammatory process including viral infections
Required prophylactic antibiotics for SBE (infectious endocarditis)
Had acute gastrointestinal symptoms at screening and/or baseline
Allergies to any of the following: lidocaine/epinephrine, articaine/epinephrine, prilocaine/epinephrine, bisulfites or metasulfites, or phentolamine
Had used any investigational drug and/or participated in any clinical trial within 30 days of baseline
Used pain relievers 24 hours prior to anesthetic administration
Required the use of nitrous oxide or sedatives to perform the scheduled, eligible dental procedure
Pregnancy, attempting to conceive,or lactating
Used decongestants or other drugs with vasoactive moieties within 24 hours prior to anesthetic administration